Investments, Funding & Disinvestment

The proposed acquisition comes at a time when radiopharmaceuticals are attracting unprecedented attention from investors, healthcare providers, and pharmaceutical manufacturers.

Edge Growth, in partnership with FNB’s Vumela Fund, backed Mia Healthcare at a pivotal stage of its development, reinforcing investor confidence in its business model and growth trajectory.

The deal gives Olympus access to BioProtect’s commercially available implant system designed to protect healthy tissue during radiation therapy.

I-MED operates a network of 215 clinics across Australia and New Zealand and performs more than seven million patient procedures annually.

Liminatus went public in 2022 through a SPAC merger and initially highlighted several immune-modulating therapies originating from research collaborations in the United States and South Korea.

Once completed, the acquisition will integrate SPR’s technology into Medtronic’s broader pain management strategy, allowing the company to offer additional options for patients and clinicians seeking alternatives to drug-based therapies.

Fujifilm Cellular Dynamics will use the expanded site to produce its iCell product portfolio, which plays a key role in new approach methods (NAMs) used in modern drug discovery and toxicity testing.

Health authorities have continued to emphasise coordinated cross-border surveillance, especially given the movement of populations between affected regions in DRC and Uganda.

The acquisition provides Gilead access to Tubulis’ proprietary ADC platforms designed to improve selective tumour targeting and payload delivery.

CVC, already the majority shareholder with a 46.8% stake, has positioned the move as a long-term strategic consolidation rather than a short-term financial transaction.